Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Prognostic Value of the Objective Prognostic Score and Palliative Prognostic Index for Short-Term Mortality in Terminal Cancer Patients Receiving Best Supportive Care: A Prospective Observational Single-Center Study.

Journal of clinical medicine·2026
Same author

Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.

Biomedicines·2026
Same author

Parameters That May Predict NAC Effectiveness in Hormone-Positive Breast Cancer According to CPS Score.

Cancer management and research·2026
Same author

Distinguishing adrenal metastases from benign lesions in NSCLC: the value of clinical and radiological parameters.

BMC cancer·2026
Same author

Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.

Diagnostics (Basel, Switzerland)·2026

相关实验视频

Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419

在NSCLC中具有驱动突变的炎症参数.

Mehmet Emin Buyukbayram1, Zekeriya Hannarici2, Ali Yilmaz3

  • 1Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.

Lung cancer management
|May 31, 2024
PubMed
概括

周围炎症标志物,如中性粒细胞-淋巴细胞比率和全身免疫炎症指数,可以预测患有驱动突变的非小细胞肺癌 (NSCLC) 患者的生存率.

关键词:
驱动器突变变异的驱动器炎症标志物的炎症标志物其他非小细胞肺癌.幸存率 幸存率 生存率

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

相关实验视频

Last Updated: Jun 25, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 非小细胞肺癌 (NSCLC) 具有驱动突变 (例如EGFR,ALK,ROS) 的瘤微环境表现出减少的炎症.
  • 了解影响这种特定NSCLC亚组生存的因素至关重要.

研究的目的:

  • 调查临床和炎症标志物与患有驱动突变的NSCLC患者的生存结果之间的关联.
  • 确定外围炎症参数是否可以预测无进展生存期 (PFS) 和整体生存期 (OS).

主要方法:

  • 对38名患有驱动突变的NSCLC患者的回顾性分析.
  • 卡普兰-梅尔曲线被用来分析临床/炎症标志物和PFS/OS之间的关系.

主要成果:

  • 65岁以下的患者具有显著更长的PFS和OS.
  • 低中性粒细胞-淋巴细胞比率 (NLR),低系统性免疫炎症指数 (SII) 和高淋巴细胞数量与明显更长的PFS和OS有关 (p <0.05).

结论:

  • 周围炎症标志物,包括NLR,SII和淋巴细胞计数,可以作为NSCLC患者生存的预后指标.
  • 这些发现表明,系统性炎症,而不是仅仅是瘤生物学,可能会影响这个患者群体的结果.